CPT® Code 86860

Official Description

Antibody elution (RBC), each elution

Common Language Description

The CPT® Code 86860 refers to the procedure known as antibody elution, specifically focusing on red blood cells (RBCs). This laboratory test is crucial for measuring the elution of antibodies from RBCs, which can be significant in various clinical scenarios. The test is typically ordered following an antibody screening that reveals the presence of IgG antibodies and/or complement fragments, which are direct anti-globulins that attach to the surface of RBCs. The presence of these antibodies is clinically important as they can lead to transfusion reactions, which may pose serious risks to patients receiving blood transfusions. Additionally, these antibodies can contribute to hemolytic disease in newborns, a condition where the mother's immune system attacks the red blood cells of the fetus or newborn. The antibody elution test serves to identify specific antibodies present in the blood, thereby assisting healthcare providers in selecting the most compatible blood products for transfusion. This is particularly vital in ensuring patient safety and minimizing the risk of adverse reactions during transfusions. Furthermore, the elution test may be ordered after a transfusion reaction has occurred, allowing for the identification of the antibodies responsible for the reaction. The procedure involves obtaining a blood sample, which is typically done through a separately reportable venipuncture. The testing of whole blood is conducted using a method known as hemagglutination, which helps in determining the presence and type of antibodies that have eluted from the RBCs.

1. Indications

The antibody elution test (CPT® Code 86860) is indicated in several clinical scenarios where the presence of antibodies on red blood cells may pose a risk to patient safety. The following conditions warrant the performance of this test:

Transfusion Reactions The test is often ordered post-transfusion when a patient experiences a transfusion reaction, allowing for the identification of specific antibodies that may have caused the adverse event.
Hemolytic Disease of the Newborn The elution test is indicated in cases where there is a concern for hemolytic disease in a newborn, as it helps identify maternal antibodies that may be affecting the infant's red blood cells.
Positive Antibody Screening The test is performed when an antibody screening test detects the presence of IgG antibodies and/or complement fragments on the surface of red blood cells, indicating the need for further investigation to ensure safe transfusion practices.

2. Procedure

The procedure for antibody elution involves several key steps that ensure accurate measurement and identification of antibodies from red blood cells. The following steps outline the process:

Step 1: Sample Collection A blood sample is obtained from the patient through a separately reportable venipuncture. This step is critical as it ensures that a sufficient volume of blood is collected for testing.
Step 2: Preparation of Red Blood Cells The collected whole blood is processed to isolate the red blood cells. This may involve centrifugation to separate the cellular components from the plasma.
Step 3: Elution Process The isolated red blood cells undergo the elution process, where specific reagents are applied to release the antibodies bound to the RBC surface. This step is essential for identifying the antibodies present.
Step 4: Testing for Antibodies The eluted antibodies are then tested using hemagglutination techniques. This method allows for the detection and identification of the specific antibodies that have been eluted from the red blood cells.

3. Post-Procedure

After the antibody elution procedure is completed, the laboratory will analyze the results to determine the presence and type of antibodies that have been eluted from the red blood cells. The findings will be documented and reported to the healthcare provider, who will use this information to make informed decisions regarding patient care, particularly in the context of transfusion compatibility. There are typically no specific post-procedure care requirements for the patient, as the procedure is performed in a laboratory setting and does not involve any invasive techniques beyond the initial venipuncture. However, it is essential for healthcare providers to monitor patients for any signs of transfusion reactions if the elution test was performed due to a previous reaction.

Short Descr	RBC ANTIBODY ELUTION
Medium Descr	ANTIBODY ELUTION RBC EACH ELUTION
Long Descr	Antibody elution (RBC), each elution
Status Code	Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days	XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC)	9 - Not Applicable
Multiple Procedures (51)	9 - Concept does not apply.
Bilateral Surgery (50)	9 - Concept does not apply.
Physician Supervisions	09 - Concept does not apply.
Assistant Surgeon (80, 82)	9 - Concept does not apply.
Co-Surgeons (62)	9 - Concept does not apply.
Team Surgery (66)	9 - Concept does not apply.
Diagnostic Imaging Family	99 - Concept Does Not Apply
APC Status Indicator	STV-Packaged Codes
Type of Service (TOS)	5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS)	T1H - Lab tests - other (non-Medicare fee schedule)
MUE	2
CCS Clinical Classification	235 - Other Laboratory

90	Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number.
26	Professional component: certain procedures are a combination of a physician or other qualified health care professional component and a technical component. when the physician or other qualified health care professional component is reported separately, the service may be identified by adding modifier 26 to the usual procedure number.
59	Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25.
GV	Attending physician not employed or paid under arrangement by the patient's hospice provider
GW	Service not related to the hospice patient's terminal condition
PD	Diagnostic or related non diagnostic item or service provided in a wholly owned or operated entity to a patient who is admitted as an inpatient within 3 days